Moteur de recherche d’entreprises européennes
Financement de l’UE (4 071 176 €) : Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease Hor01/11/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease
The RenalToolBox ITN comprises a team of world-leading clinicians, scientists and industrialists from academia and private enterprise whose common goal is to develop innovative medical devices and imaging technologies to expedite the translation of cell-based regenerative medicine therapies (RMTs) to the clinic. The target disease for RenalToolBox is kidney disease, the incidence of which is increasing annually. The ITN provides an excellent framework for training 15 early stage researchers (ESRs) in a range of technological, entrepreneurial and transferable skills that will not only enhance their career prospects, but will also boost European scientific excellence and business innovation. By the end of the programme, the ESRs will have benefitted from a comprehensive multidisciplinary and multi-sectoral training experience that will equip them to expedite progress in the emerging supradisciplinary fields of biomedical devices, bio-imaging, cellular therapeutics and regenerative medicine. The research training objectives are as follows: 1. Train the young researchers in the development of diagnostic devices and novel tracers for monitoring renal function. 2. Apply cutting-edge imaging technologies to evaluate the safety and efficacy of novel cell-based RMTs in a rodent model of kidney disease. 3. Assess the safety and efficacy of different sources of mesenchymal stromal cells and explore the mechanisms whereby these cells can ameliorate kidney disease. This comprehensive training programme will endow the young researchers with the necessary scientific and industrial skills to ensure their employability and readiness to engage and lead the next European generation of scientists-entrepreneurs.
| Katholieke Universiteit Leuven | ? |
| ACADEMISCH ZIEKENHUIS LEIDEN | 265 620 € |
| Cyanagen Srl | 261 500 € |
| ITHERA MEDICAL GmbH | 252 788 € |
| NHS Blood and Transplant | 303 173 € |
| RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG | 1 011 154 € |
| The University of Liverpool | 909 518 € |
| Universita Degli Studi Di Torino | 261 500 € |
| UNIVERSITEIT UTRECHT | 531 240 € |
| University of Galway | 274 684 € |
https://cordis.europa.eu/project/id/813839
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Katholieke Universiteit Leuven privaatrechtelijke rechtspersoon, Leuven, Belgique.
Les visualisations de "Katholieke Universiteit Leuven - Financement de l’UE (4 071 176 €) : Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
